TOKYO -- Japanese biotech startup Orizuru Therapeutics will start clinical trials as soon as fiscal 2027 for a diabetes treatment using induced pluripotent (iPS) stem cells that could reduce insulin doses needed to lower blood sugar levels, potentially transforming the way the disease is treated.